Navigation Links
ESTEVE Fosters R & D by Transferring its Center for Drug Discovery to the Science Park of Barcelona (PCB)
Date:9/19/2012

BARCELONA, Spain, September 19, 2012 /PRNewswire/ --

ESTEVE's R & D team includes a total of 350 people, 13% of the total global workforce, with the capability to work in all areas of drug discovery and the development of new medicines. This new R&D Center will house 92 scientists focused on two key phases in drug development; (1) The discovery phase, the phase during which new chemical entities are identified that may have the ability to positively change the course of a disease and, (2) the preclinical development phase, which includes performing all the necessary tests to provide the appropriate evidence to allow a new drug to be evaluated in humans.

The transfer to the PCB is an example of ESTEVE's commitment to research, despite the difficult socio-economic environment, as a way to maintain long-term sustainability. One of the keys to this sustainability is the ability to provide innovative solutions to medical needs that have not yet been adequately met. In this new facility, the company expects to increase performance in its R & D activities, improving the overall productivity of the discovery process in the development of new drugs and shorten the time to market.

This is the first alliance of its kind, where a large pharmaceutical company will locate all key competence units for drug discovery and preclinical development in a top quality academic / scientific environment in Spain.

The decision-making process to transfer the R & D team to the PCB took into consideration several factors, the most notable of which is the excellent infrastructure, the advantages of working in a high quality scientific and technical environment and the presence, in a common area, of scholars, researchers, talented young people and groups of entrepreneurs. It represents a further step towards a single model of open innovation in pharmaceutical R & D. ESTEVE's key strategy in R & D is an active policy of creating strategic alliances with universities, public research centres, technology companies and other companies in the sector, both in Spain and abroad

For more information go to http://www.esteve.com/investigacion-desarrollo


'/>"/>
SOURCE ESTEVE
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ESTEVE Announces Publication of Key Preclinical Data for a Novel Oral, First-in-class New Chemical Entity (NCE) Sigma-1 Receptor Antagonist (E-52862), that has Completed Phase I and Initiated its Phase II Clinical Trial Program
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Smith & Nephew launches revolutionary open-architecture suture anchor for rotator cuff repair with greater pullout strength than competitors[i]
4. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
5. Biopharma M&A Trends Hold Steady, But Deals Declined in 2011
6. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
7. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
8. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
9. Ultra Clean to Present at the Jefferies 2012 Global Technology, Media & Telcom Conference
10. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
11. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2020)... ... January 23, 2020 , ... FiteBac® Cavity ... exposed dentin tubules allowing restorative adhesives to tightly bind to the prepared dentin ... FiteBac® Cavity Cleanser with 2% K21. Cavity cleansers are intended for cleansing ...
(Date:1/23/2020)... (PRWEB) , ... January 23, 2020 , ... Please join ... she begins her term as the Society’s president for 2020. Dr. Dorbala is the ... and is an associate professor of radiology at Harvard. Over more than 20 years ...
(Date:1/23/2020)... ... , ... “It’s complicated.” The phrase may apply to some ... a person’s hand, wrist, arm and shoulder. “Which is why patients should contact ... goes wrong up or down this superhighway of interconnected bones, joints, tendons, ligaments, ...
Breaking Medicine Technology:
(Date:1/24/2020)... ... January 24, 2020 , ... SweetLeaf Stevia ... expert and best-selling nutrition author Jorge Cruise to educate consumers on losing weight ... an enthusiastic advocate of intermittent fasting, that is fat burning and boosting your ...
(Date:1/23/2020)... ... ... SignatureCare Emergency Center is set to expand to North Dallas with the opening of ... of Lewisville, on 1596 W. Main St., Lewisville, TX 75067, the new location will ... It will serve residents and businesses around Lewisville, TX, including Double Oak, Copper Canyon, ...
(Date:1/23/2020)... ... January 23, 2020 , ... ... impairment, has announced the Best Memory Care Facilities in Santa Rosa, California. The ... features and amenities. , According to the Alzheimer’s Association , 5.6 ...
(Date:1/23/2020)... ... January 23, 2020 , ... ... and services that improve workforce resilience, is presenting at the NATSAP 2020 Conference. ... advocate and resource for organizations that devote themselves to society’s need for the ...
(Date:1/23/2020)... ... January 23, 2020 , ... This week, SocialClimb ... to power the Arrowlytics platform and deliver its key performance indicators (KPIs) to ... with practice management systems to extract the data necessary to enable Arrowlytics. , ...
Breaking Medicine News(10 mins):